Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adagene Inc. - ADS, each representing 1.25 ordinary shares
(NQ:
ADAG
)
1.790
+0.010 (+0.56%)
Streaming Delayed Price
Updated: 3:59 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adagene Inc. - ADS, each representing 1.25 ordinary shares
< Previous
1
2
Next >
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
November 13, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
September 05, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
September 03, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Participate in Two Investor Conferences in September
August 26, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
August 12, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
July 15, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
July 08, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene announces up to $25 million strategic investment from Sanofi
July 01, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at Jefferies Global Healthcare Conference 2025
May 27, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
April 28, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
April 07, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
March 24, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
March 13, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at Leerink’s Global Healthcare Conference 2025
March 06, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
February 27, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
January 27, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
January 21, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
January 14, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
November 07, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 09, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
September 16, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Participate in Investor Conferences in September
August 29, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
July 25, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
July 12, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at Investor Conferences in June
May 22, 2024
From
Adagene Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
